Avni Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
- Revenue Growth 100.63%
- Profit Growth -8.54%
- Ebitda 47.35%
- Net Worth 7.00%
- Total Assets 25.52%
About Avni Pharmaceuticals
Avni Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 December 2010 and has a history of 14 years and two months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Suvarna Reddy and Vidya Govind serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232PN2010PTC137904
- Company No.
137904
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does Avni Pharmaceuticals Private Limited offer?
Avni Pharmaceuticals Private Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Disposable Cannulas.
Who are the key members and board of directors at Avni Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suvarna Reddy  | Director | 15-Dec-2022 | Current |
| Vidya Govind | Director | 15-Dec-2022 | Current |
Financial Performance of Avni Pharmaceuticals.
Avni Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 100.63% increase. The company also saw a slight decrease in profitability, with a 8.54% decrease in profit. The company's net worth moved up by a moderate rise of 7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avni Pharmaceuticals?
In 2023, Avni Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Jul 2021 | Canara Bank | ₹1.00 M | Open |
How Many Employees Work at Avni Pharmaceuticals?
Unlock and access historical data on people associated with Avni Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avni Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avni Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
